Sopharma AD

Transaction in Own Shares • Jun 18, 2020

Notification for technical error correction

Sofia, Bulgaria, June 18, 2020 - According to the requirements of art. 111, para. 8 of LPOS "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that due to a technical error in the Notification for treasury shares, number 194-00-31 / 16.06.2020 should be read:

"Sofia, Bulgaria, June 16, 2020 - According to the requirements of art. 111, para. 8 of LPOS "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on June 15, 2020 the Company sold 85 748 own shares representing 0.0636% of the share capital of the Company, at a total value of 277 823,52 BGN on the Bulgarian Stock Exchange, the average price per share was 3.240 BGN.

The total number of treasury shares after this transaction is 9 114 467, representing 6.762% of the share capital of the Company."

We apologize for the inconvenience.

___________________________

Pelagia Viatcheva

Investor Relations Director

Information about the company

Sopharma AD

85 years of tradition and modernity - modern production, European standards and quality of production, corporate and social responsibility.

Today Sopharma is the most successful Bulgarian company after privatization, as from 2000 years to today, the company realized 10 times growth in market capitalization and 25 times revenue growth. Over the past 10 years, Sopharma has been the first in revenue in the pharmaceutical sector in Bulgaria.

With 10 pharmaceutical plants in the country and the only ampoule factory in Bulgaria with 24,000 ampoules per hour, it produces 3 billion tablets, 20 million syrup forms, 210 generic products, 15 original formulas, 12 plant-based products and uses 1500 tons of medicinal plants in their products.

1756 Sofia www.sopharmagroup.com 5 Lachezar Stanchev Str. tel: +359 (0) 2 4055 319; +359 (0) 8134 319 Sopharma Business Towers, Tower А, fl. 11 fax: +359 (0) 2 4055 141; +359 (0) 8134 141

Sopharma AD has an active and key role in raising the standard of living in making people healthier, happier and protected. Sopharma is constantly investing in new technologies, innovations and research. We are creating a permanent and effective dialogue with all stakeholders in the pharmaceutical industry that contribute to improving the healthcare system.

The company produces active substances and medicinal products; conducts activities related to research, development and implementation in the field of phytochemistry, chemistry and pharmacy. Sopharma AD provides services related to production as well as other related services.

Sopharma Group

Sopharma Group is a vertically integrated healthcare business that operates in important sectors such as pharmaceuticals, hospital supplies, drug distribution (GDP standardized) and many others. Sopharma and its production subsidiaries have 12 pharmaceutical plants in Bulgaria, complying with EU requirements - GMP, a factory in Ukraine certified by local authorities.